Bringing Psychedelic Therapy into Public Health Care

Psychedelic-assisted psychotherapy is entering mainstream discourse, and the MIND Foundation is a key actor in bringing this treatment into the public health insurance system. We recently completed the world’s largest publicly funded (BMBF) clinical trial with psilocybin for depression as junior partners of ZI Mannheim and Charité Berlin. MIND is now preparing a phase-III trial that will bring psilocybin therapy to patients in a legal, safe, evidence-based, and accessible way.

A value-based scientific approach is crucial for a sustainable re-introduction of psychedelic substances, especially now in times of growing public interest.

We need to be clear about both potentials and risks of psychedelics as we take it out of a niche and into the center of society. 

Program

16:00 – 17:00 Uhr
Doors open
Immersive VR experience, networking

17.00 – 17:45 Uhr
Current state of psychedelic therapies within the German health care system
Dr. med. Andrea Jungaberle

17.45 – 18:15 Uhr
Preparing, experiencing and integrating psilocybin therapy - stories from patients
Christopher Schmidt, M.Sc.

18:30 – 19:00 Uhr
Ketamine-Augmented Psychotherapy in Practice
Dr. med. Marc Bos

19:00 – 19.30 Uhr
From niche to mainstream: The role of MIND’s non-clinical psychedelic integration programs
Victor Jivanescu, M.Sc.

19:30 – 20:00 Uhr
What we need to bring psychedelic therapy into public health care
Dr. Henrik Jungaberle

20:00
Networking